{"classes":[{"categories":[{"measurements":[{"comment":"Median DOR is Not Available (NA) because none of the patients with a confirmed CR or PR had experienced radiographic or PSA progression at data cutoff. Over 50% remained progression-free, so the median could not be estimated.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"median, upper and lower bounds of 95% Confidence Interval could not be estimated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"3.15","upperLimit":"NA","value":"12.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Duration of Response (DOR) defined as the time from the first documented CR or PR until radiograph disease progression or Prostate-Specific Antigen (PSA) progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nCisplatin: Given IV\n\nDocetaxel: Given IV\n\nEtoposide: Given IV\n\nPembrolizumab: Given IV","id":"OG000","title":"Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer"},{"description":"Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Cohort 2: Small Cell or Neuroendocrine Prostate Cancer"}],"paramType":"MEDIAN","populationDescription":"one patient withdrew Cohort 2","reportingStatus":"POSTED","timeFrame":"From the first documented CR or PR up to 3 years","title":"Duration of Response (DOR) Per RECIST 1.1 (Cohorts 1 and 2)","type":"PRIMARY","unitOfMeasure":"Months"}